Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | PAM | P19021 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911400 | 0.84 | GGPS1 (0.51) | — | |
| SCHEMBL1685302 | 0.80 | KEAP1 (0.55) | L3MBTL1ALDH1A1MAPK1ANPEPHDAC8 | |
| SCHEMBL77563 | 0.79 | CES1 (0.70) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL4944887 | 0.78 | CTBP2 (0.51) | MEN1KMT2AALDH1A1HDAC8HDAC6 | |
| SCHEMBL9041685 | 0.77 | HDAC1 (0.58) | CES1MAPK1HDAC8HDAC6TDP1 | |
| SCHEMBL21171794 | 0.77 | S1PR2 (0.47) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL758293 | 0.77 | TSHR (0.47) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL2208952 | 0.77 | CETP (0.48) | CES1CES2AKR1B1L3MBTL1ALDH1A1 | |
| SCHEMBL9693670 | 0.77 | CES1 (0.67) | CES1CES2AKR1B1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27690655 | 0.77 | CES1 (0.67) | CES1CES2AKR1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| US-7419999-B2 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-09-02 | — | — | US | disclosed |
| CN-101189248-A | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-28 | — | — | CN | disclosed |
| CN-101180097-A | Novel phosphinic acid-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-14 | — | — | CN | disclosed |
| CN-1882327-A | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-1556347-A4 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2006-08-09 | — | — | EP | disclosed |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | disclosed |
| EP-1556347-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-27 | — | — | EP | disclosed |
| US-4036832-A | 15-Substituted-ω-pentanorprostaglandins | PFIZER INC. (US) | 1977-07-19 | — | — | US | disclosed |
| US-4035360-A | TISSUE SPECIFICITY, CRYSTALLINE | PFIZER INC. (US) | 1977-07-12 | — | — | US | disclosed |
| US-4029814-A | ANTIULCER, ANTICOAGULANT, DECONGESTANT, OXYTOCIC | THE UPJOHN COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
| US-4018892-A | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters | PFIZER INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-4011262-A | 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series | PFIZER INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-4000309-A | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters | PFIZER INC. (US) | 1976-12-28 | — | — | US | disclosed |
| US-3984424-A | MEDICAMENTS | PFIZER INC. (US) | 1976-10-05 | — | — | US | disclosed |
| US-3982016-A | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters | PFIZER INC. (US) | 1976-09-21 | — | — | US | disclosed |
| US-3971826-A | 15-Substituted-ω-pentanorprostaglandins | PFIZER INC. (US) | 1976-07-27 | — | — | US | disclosed |
| US-3932389-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | CES1 954/4885CES2 2523/4885AKR1B1 1499/4885 |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | PGF, HPGDS, PTGIS | CES1 927/4885CES2 2628/4885AKR1B1 1925/4885 |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | HCAR1, NAA40, HCAR2 | CES1 224/4885CES2 805/4885AKR1B1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.